This Is What Whales Are Betting On ADMA Biologics
Portfolio Pulse from Benzinga Insights
High-rolling investors are showing a bearish sentiment on ADMA Biologics (NASDAQ:ADMA) through options trading, with 71% of trades being bearish. The stock is currently down 18.28% at $16.61, and RSI indicators suggest it may be oversold. An analyst from Cantor Fitzgerald has revised the rating to Overweight with a price target of $20.
October 10, 2024 | 4:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
ADMA Biologics is experiencing significant bearish sentiment from high-rolling investors, with 71% of options trades being bearish. The stock is down 18.28% at $16.61, and RSI indicators suggest it may be oversold. An analyst has set a price target of $20.
The significant bearish sentiment from high-rolling investors, as indicated by 71% bearish options trades, suggests a negative short-term outlook for ADMA Biologics. The stock's current decline of 18.28% and RSI indicators pointing to oversold conditions further support this bearish view. Additionally, the analyst's price target of $20, while higher than the current price, does not negate the immediate bearish sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100